Back to Search
ROBERT SCHIFF, PH.D.
PH.D.
Clinical Psychologist
NPI: 1508879040Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
OR 573(OR)
Research & Publications (20)
Morphological analogies in Hebrew-speaking university students with dyslexia compared with typically developing gradeschoolers.
PMID 17205394·J Psycholinguist Res·2007
8-other
Deficient morphological processing in adults with developmental dyslexia: another barrier to efficient word recognition?
PMID 17557687·Dyslexia·2007
8-other
Living wills and the Mental Capacity Act: a postal questionnaire survey of UK geriatricians.
PMID 16414962·Age Ageing·2006
8-other
Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?
PMID 16520802·Nat Clin Pract Oncol·2006
8-other
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
PMID 16168139·Breast Cancer Res·2005
8-other
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
PMID 16273359·Cancer Chemother Pharmacol·2005
6-review
Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study.
PMID 15694110·Psychoneuroendocrinology·2005
3-trial
Representing written vowels in university students with dyslexia compared with normal Hebrew readers.
PMID 15765003·Ann Dyslexia·2004
8-other
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
PMID 14734488·Clin Cancer Res·2004
7-preclinical
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).
PMID 12927029·Breast Cancer Res·2003
6-review
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
PMID 12538499·Clin Cancer Res·2003
6-review
Distribution and morphology of transgenic mouse oligodendroglial-lineage cells following transplantation into normal and myelin-deficient rat CNS.
PMID 11920719·J Comp Neurol·2002
7-preclinical
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
PMID 11106684·J Natl Cancer Inst·2000
7-preclinical
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
PMID 18807177·Breast Cancer Res Treat·2009
8-other
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
PMID 19584166·Clin Cancer Res·2009
7-preclinical
Advance end-of-life healthcare planning in an acute NHS hospital setting; development and evaluation of the Expression of Healthcare Preferences (EHP) document.
PMID 19029089·Age Ageing·2009
8-other
Spongiform pathology in mouse CNS lacking 'neuropathy target esterase' and cellular prion protein.
PMID 19524041·Neurobiol Dis·2009
7-preclinical
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
PMID 18294736·Neurobiol Aging·2009
3-trial
Molecular profiles of progesterone receptor loss in human breast tumors.
PMID 18425577·Breast Cancer Res Treat·2009
4-observational
Spinal cord dysmyelination caused by an antiproteolipid protein IgM antibody: implications for the mechanism of central nervous system myelin formation.
PMID 18951490·J Neurosci Res·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5125 SKYLINE RD S
SALEM, OR 97306 - Phone
- (503) 588-5955
Quick Facts
- NPI
- 1508879040
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile